Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 24 of 99

  1. CAN-2409 + valacyclovir

    Candel Therapeutics

    Lung Cancer

    phase 1 mab completed

    1 trial

  2. CAR T cells

    Qian Wenbin

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  3. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  4. CAR T-cell therapy

    Hospital Authority, Hong Kong

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 mab active

    1 trial

  5. CAR-BCMA T cells

    The First People's Hospital of Lianyungang

    Refractory or Relapsed Multiple Myeloma

    phase 1 gene therapy active

    1 trial

  6. CAR-T

    The Third Affiliated Hospital of Southern Medical University

    Multiple Myeloma

    phase 1 mab active

    1 trial

  7. CAR-T Re-treatment

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  8. CAR-T Therapy

    Zhao Weili

    Peripheral T Cell Lymphoma

    phase 1 small molecule active

    1 trial

  9. CAR-T cell infusion

    The First People's Hospital of Lianyungang

    Hematolymphoid Malignancies

    phase 1 small molecule active

    1 trial

  10. CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Relapsed Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  11. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  12. CAR-T cells chimenric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  13. CAR-T cells chimeric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia(AML)

    phase 1 small molecule active

    1 trial

  14. CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

    The George Institute

    Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.

    phase 1 other active

    1 trial

  15. CART19 cell and auto-HSCT

    Shenzhen Second People's Hospital

    Leukemia, Lymphocytic, Acute, B-Cell

    phase 1 mab active

    1 trial

  16. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  17. CB-010

    Caribou Biosciences

    Lymphoma, Non-Hodgkin

    phase 1 gene therapy active

    1 trial

  18. CB-010

    Caribou Biosciences

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial

  19. CB-011

    Caribou Biosciences

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  20. CB-012

    Caribou Biosciences

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule terminated

    1 trial

  21. CB-03-01/39

    Cassiopea S.p.A.

    Test of vasocontriction properties for classification of topical steroid potency

    phase 1 other active

    1 trial

  22. CBD Day 1

    BRIGHT MINDS BIOSCIENCES INC.

    Addiction

    phase 1 small molecule completed

    1 trial

  23. CBD-OS

    Jazz Pharmaceuticals Ireland Limited

    Focal Seizures

    phase 1 small molecule active

    1 trial

  24. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  25. CBP-174

    S.L

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial

  26. CBP-201-CN004

    S.L

    Healthy Adult Subjects

    phase 1 mab completed

    1 trial

  27. CBP-307

    Connect Biopharm

    Autoimmune Diseases

    phase 1 small molecule completed

    1 trial

  28. CBP-307

    S.L

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial

  29. CBP-307

    S.L

    Autoimmune Diseases

    phase 1 small molecule completed

    2 trials

  30. CBR-CMR316-3001

    The George Institute

    Idiopathic Pulmonary Fibrosis

    phase 1 other active

    1 trial

  31. CBS001

    Centessa Pharmaceuticals plc

    Chronic Inflammatory Disease

    phase 1 small molecule terminated

    1 trial

  32. CBT124

    Cipla (EU) Limited

    Healthy

    phase 1 mab active

    1 trial

  33. CC-122

    Bristol-Myers Squibb

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  34. CC-486

    Celgene Europe Limited

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  35. CC-90010-GBM-002

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  36. CC-90010-ST-001

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  37. CC-90011-SCLC-001

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  38. CCHF-NP-1

    The George Institute

    Crimean Congo Hemorrhagic Fever

    phase 1 other active

    1 trial

  39. CCT3833

    United Therapeutics Europe Ltd

    Melanoma

    phase 1 small molecule completed

    1 trial

  40. CD-001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  41. CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

    United Therapeutics Europe Ltd

    HER2 Negative Breast Carcinoma

    phase 1 mab active

    1 trial

  42. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  43. CD19 and BCMA-targeted allogeneic CAR-T cells

    The First People's Hospital of Lianyungang

    Refractory Immune-mediated Platelet Transfusion Refractoriness

    phase 1 gene therapy active

    1 trial

  44. CD19 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    SLE (Systemic Lupus)

    phase 1 mab active

    1 trial

  45. CD19-CD22 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  46. CD19-STAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B Cell Malignancy

    phase 1 mab completed

    1 trial

  47. CD19-TriCAR-T/SILK

    Biotech Pharmaceutical Co.,

    Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  48. CD19-targetd CAR-T

    Chongqing Precision Biotech Co., Ltd

    Juvenile Dermatomyositis

    phase 1 mab active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.